# Philippe Clzardin

## List of Publications by Year in Descending Order



| | | | |
|---|---|---|---|
| 162 papers | 8,268 citations | 54 h-index | 86 g-index |
| 200 ext. papers | 9,112 ext. citations | 6.6 avg, IF | 6.1 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 162 | MicroRNAs and bone metastasis **2022**, 457-469 | | |
| 161 | Fracture Risk Evaluation of Bone Metastases: A Burning Issue. *Cancers*, **2021**, 13, | 6.6 | 1 |
| 160 | MicroRNAs and Their Roles in Breast Cancer Bone Metastasis. *Current Osteoporosis Reports*, **2021**, 19, 256-263 | 5.4 | 3 |
| 159 | Bone metastasis: mechanisms, therapies, and biomarkers. *Physiological Reviews*, **2021**, 101, 797-855 | 47.9 | 25 |
| 158 | Non-coding RNAs in bone remodelling and bone metastasis: Mechanisms of action and translational relevance. *British Journal of Pharmacology*, **2021**, 178, 1936-1954 | 8.6 | 14 |
| 157 | Knockdown of AKT3 Activates HER2 and DDR Kinases in Bone-Seeking Breast Cancer Cells, Promotes Metastasis In Vivo and Attenuates the TGF/CTGF Axis. *Cells*, **2021**, 10, | 7.9 | 6 |
| 156 | Integrin alpha5 in human breast cancer is a mediator of bone metastasis and a therapeutic target for the treatment of osteolytic lesions. *Oncogene*, **2021**, 40, 1284-1299 | 9.2 | 16 |
| 155 | ERRExpression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response. *Cancer Research*, **2020**, 80, 2914-2926 | 10.1 | 6 |
| 154 | Long-Term Exposure of Early-Transformed Human Mammary Cells to Low Doses of Benzo[a]pyrene and/or Bisphenol A Enhances Their Cancerous Phenotype via an AhR/GPR30 Interplay. *Frontiers in Oncology*, **2020**, 10, 712 | 5.3 | 3 |
| 153 | The CaSR in Pathogenesis of Breast Cancer: A New Target for Early Stage Bone Metastases. *Frontiers in Oncology*, **2020**, 10, 69 | 5.3 | 14 |
| 152 | Bone metastases. *Nature Reviews Disease Primers*, **2020**, 6, 83 | 51.1 | 77 |
| 151 | Current and Emerging Bone-Targeted Therapies for The Treatment of Bone Metastases From Solid Tumors **2020**, 403-420 | | |
| 150 | The RANK-RANKL axis: an opportunity for drug repurposing in cancer?. *Clinical and Translational Oncology*, **2019**, 21, 977-991 | 3.6 | 16 |
| 149 | Bone metastases in the era of targeted treatments: insights from molecular biology. *Quarterly Journal of Nuclear Medicine and Molecular Imaging*, **2019**, 63, 98-111 | 1.4 | 7 |
| 148 | Bone Metastases; Basic Aspects **2019**, 304-309 | | |
| 147 | ERRpromotes breast cancer cell dissemination to bone by increasing RANK expression in primary breast tumors. *Oncogene*, **2019**, 38, 950-964 | 9.2 | 19 |
| 146 | Bone, muscle, and metabolic parameters predict survival in patients with synchronous bone metastases from lung cancers. *Bone*, **2018**, 108, 202-209 | 4.7 | 29 |

| | | | |
|---|---|---|---|
| 145 | miRNA-30 Family Members Inhibit Breast Cancer Invasion, Osteomimicry, and Bone Destruction by Directly Targeting Multiple Bone Metastasis-Associated Genes. *Cancer Research*, **2018**, 78, 5259-5273 | 10.1 | 98 |
| 144 | Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. *Clinical Breast Cancer*, **2018**, 18, e1311-e1321 | 3 | 6 |
| 143 | The C-Terminal Intact Forms of Periostin (iPTN) Are Surrogate Markers for Osteolytic Lesions in Experimental Breast Cancer Bone Metastasis. *Calcified Tissue International*, **2018**, 103, 567-580 | 3.9 | 9 |
| 142 | Bone-Targeted Therapies in Cancer-Induced Bone Disease. *Calcified Tissue International*, **2018**, 102, 227-250 | 3.9 | 58 |
| 141 | TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases. *Cancer Letters*, **2018**, 438, 32-43 | 9.9 | 12 |
| 140 | Physiopathologie des mÉtastases osseuses des tumeurs solides. *Revue Du Rhumatisme Monographies*, **2017**, 84, 107-114 | 0 | 0 |
| 139 | Pathophysiology of bone metastases from solid malignancies. *Joint Bone Spine*, **2017**, 84, 677-684 | 2.9 | 27 |
| 138 | Lysyl Oxidase Is a Strong Determinant of Tumor Cell Colonization in Bone. *Cancer Research*, **2017**, 77, 268-278 | 10.1 | 44 |
| 137 | Effect of intra-tibial injection on mechanical properties of mouse bone. *Computer Methods in Biomechanics and Biomedical Engineering*, **2017**, 20, 57-58 | 2.1 | 2 |
| 136 | Overexpression of a functional calcium-sensing receptor dramatically increases osteolytic potential of MDA-MB-231 cells in a mouse model of bone metastasis through epiregulin-mediated osteoprotegerin downregulation. *Oncotarget*, **2017**, 8, 56460-56472 | 3.3 | 18 |
| 135 | Unseeded Inertial Cavitation for Enhancing the Delivery of ´Chemotherapies: A Safety Study. *Ultrasound in Medicine and Biology*, **2016**, 42, 220-31 | 3.5 | 15 |
| 134 | Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. *Annals of Oncology*, **2016**, 27, 379-90 | 10.3 | 135 |
| 133 | Estrogen related receptor alpha in castration-resistant prostate cancer cells promotes tumor progression in bone. *Oncotarget*, **2016**, 7, 77071-77086 | 3.3 | 21 |
| 132 | Cancer Cell Colonisation in the Bone Microenvironment. *International Journal of Molecular Sciences*, **2016**, 17, | 6.3 | 59 |
| 131 | The role of osteoclasts in breast cancer bone metastasis. *Journal of Bone Oncology*, **2016**, 5, 93-95 | 4.5 | 48 |
| 130 | Physiopathologie des mÉtastases osseuses. *Oncologie*, **2015**, 17, 69-74 | 1 | |
| 129 | Tumour-derived miRNAs and bone metastasis. *BoneKEy Reports*, **2015**, 4, 688 | | 31 |
| 128 | MicroRNA-mediated regulation of bone metastasis formation: from primary tumors to skeleton **2015**, 479-489 | | 3 |

| | | | |
|---|---|---|---|
| 127 | Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma. *BoneKEy Reports*, **2015**, 4, 744 | | 12 |
| 126 | Low-Intensity Ultrasound Promotes Clathrin-Dependent Endocytosis for Drug Penetration into Tumor Cells. *Ultrasound in Medicine and Biology*, **2015**, 41, 2740-54 | 3.5 | 16 |
| 125 | Upregulation of the mevalonate pathway by cholesterol depletion abolishes tolerance to N-bisphosphonate induced Vγ9Vδ2 T cell cytotoxicity in PC-3 prostate cancer cells. *Cancer Letters*, **2015**, 357, 279-285 | 9.9 | 5 |
| 124 | Low-intensity continuous ultrasound triggers effective bisphosphonate anticancer activity in breast cancer. *Scientific Reports*, **2015**, 5, 16354 | 4.9 | 13 |
| 123 | Emerging therapies in bone metastasis. *Current Opinion in Pharmacology*, **2015**, 22, 79-86 | 5.1 | 25 |
| 122 | The LPA1/ZEB1/miR-21-activation pathway regulates metastasis in basal breast cancer. *Oncotarget*, **2015**, 6, 20604-20 | 3.3 | 46 |
| 121 | Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity. *Journal of Biological Chemistry*, **2014**, 289, 6551-6564 | 5.4 | 34 |
| 120 | TRPV6 calcium channel translocates to the plasma membrane via Orai1-mediated mechanism and controls cancer cell survival. *Proceedings of the National Academy of Sciences of the United States of America*, **2014**, 111, E3870-9 | 11.5 | 73 |
| 119 | TWIST1 expression in breast cancer cells facilitates bone metastasis formation. *Journal of Bone and Mineral Research*, **2014**, 29, 1886-99 | 6.3 | 54 |
| 118 | Interaction of platelet-derived autotaxin with tumor integrin αVβ3 controls metastasis of breast cancer cells to bone. *Blood*, **2014**, 124, 3141-50 | 2.2 | 108 |
| 117 | Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers. *PLoS ONE*, **2014**, 9, e97771 | 3.7 | 17 |
| 116 | Combination of anti-angiogenic therapies reduces osteolysis and tumor burden in experimental breast cancer bone metastasis. *International Journal of Cancer*, **2014**, 135, 1319-29 | 7.5 | 17 |
| 115 | Mutational profiling of bone metastases from lung adenocarcinoma: results of a prospective study (POUMOS-TEC). *BoneKEy Reports*, **2014**, 3, 580 | | 20 |
| 114 | Os, cible thérapeutique (RPC 2013). *Oncologie*, **2013**, 15, 673-686 | 1 | 2 |
| 113 | Peroxiredoxin 2 specifically regulates the oxidative and metabolic stress response of human metastatic breast cancer cells in lungs. *Oncogene*, **2013**, 32, 724-35 | 9.2 | 72 |
| 112 | Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. *BoneKEy Reports*, **2013**, 2, 267 | | 56 |
| 111 | A transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasis. *Molecular and Cellular Proteomics*, **2013**, 12, 2111-25 | 7.6 | 25 |
| 110 | Increased expression of putative cancer stem cell markers in the bone marrow of prostate cancer patients is associated with bone metastasis progression. *Prostate*, **2013**, 73, 1738-46 | 4.2 | 25 |

| | | | |
|---|---|---|---|
| 109 | A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. *PLoS ONE*, **2013**, 8, e75092 | 3.7 | 21 |
| 108 | Pourquoi certains cancers m□astasent-ils pr□□entiellement □l□s ?. *Oncologie*, **2012**, 14, 31-36 | 1 | 1 |
| 107 | Differential proteomic analysis of a human breast tumor and its matched bone metastasis identifies cell membrane and extracellular proteins associated with bone metastasis. *Journal of Proteome Research*, **2012**, 11, 2247-60 | 5.6 | 19 |
| 106 | RANK/RANKL pathway in cancer: Biological activity beyond bone?. *Journal of Bone Oncology*, **2012**, 1, 67-8 | 4.5 | 1 |
| 105 | Targeting heat shock protein 27 (HspB1) interferes with bone metastasis and tumour formation in vivo. *British Journal of Cancer*, **2012**, 107, 63-70 | 8.7 | 60 |
| 104 | Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. *Cancer Treatment Reviews*, **2012**, 38, 407-15 | 14.4 | 133 |
| 103 | Targeting lysophosphatidic acid receptor type 1 with Debio 0719 inhibits spontaneous metastasis dissemination of breast cancer cells independently of cell proliferation and angiogenesis. *International Journal of Oncology*, **2012**, 40, 1133-41 | 4.4 | 49 |
| 102 | Increased expression of putative cancer stem cell markers in primary prostate cancer is associated with progression of bone metastases. *Prostate*, **2012**, 72, 713-20 | 4.2 | 47 |
| 101 | Bioluminescence imaging of prenylation inhibition--letter. *Clinical Cancer Research*, **2012**, 18, 6077; author reply 6078 | 12.9 | |
| 100 | In vivo phosphoantigen levels in bisphosphonate-treated human breast tumors trigger V□V□ T-cell antitumor cytotoxicity through ICAM-1 engagement. *Clinical Cancer Research*, **2012**, 18, 6249-59 | 12.9 | 41 |
| 99 | Potential anticancer properties of bisphosphonates: insights from preclinical studies. *Anti-Cancer Agents in Medicinal Chemistry*, **2012**, 12, 102-13 | 2.2 | 24 |
| 98 | Effects of bone-targeted agents on cancer progression and mortality. *Journal of the National Cancer Institute*, **2012**, 104, 1059-67 | 9.7 | 157 |
| 97 | Overexpression of CD9 in human breast cancer cells promotes the development of bone metastases. *Anticancer Research*, **2012**, 32, 5211-20 | 2.3 | 33 |
| 96 | Bisphosphonates' antitumor activity: an unravelled side of a multifaceted drug class. *Bone*, **2011**, 48, 71-9 | 4.7 | 129 |
| 95 | Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. *Bone*, **2011**, 48, 259-66 | 4.7 | 72 |
| 94 | Bisphosphonates in preclinical bone oncology. *Bone*, **2011**, 49, 66-70 | 4.7 | 46 |
| 93 | 1074 POSTER Effects of Zoledronic Acid and Denosumab on Human Vy9V62 T-cell-Mediated Cell Death of RANK-Expressing Breast Cancer Cells. *European Journal of Cancer*, **2011**, 47, S117 | 7.5 | 2 |
| 92 | Therapeutic targets for bone metastases in breast cancer. *Breast Cancer Research*, **2011**, 13, 207 | 8.3 | 80 |

| | | | |
|---|---|---|---|
| 91 | Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. *PLoS ONE*, **2011**, 6, e19234 | 3.7 | 136 |
| 90 | Increased expression and serum levels of the stromal cell-secreted protein periostin in breast cancer bone metastases. *International Journal of Cancer*, **2011**, 128, 352-60 | 7.5 | 65 |
| 89 | High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. *Cancer Research*, **2011**, 71, 4562-72 | 10.1 | 116 |
| 88 | Clinical and basic research papers □February 2011. *IBMS BoneKEy*, **2011**, 8, 65-73 | | |
| 87 | Clinical and basic research papers □July 2011. *IBMS BoneKEy*, **2011**, 8, 305-312 | | |
| 86 | Clinical and basic research papers □November-December 2011. *IBMS BoneKEy*, **2011**, 8, 305-312 | | |
| 85 | Can bisphosphonates really reduce the risk of recurrences in early breast cancer?. *IBMS BoneKEy*, **2011**, 8, 159-164 | | 1 |
| 84 | Clinical and basic research papers □September 2011. *IBMS BoneKEy*, **2011**, 8, 390-396 | | |
| 83 | Dual function of ERR□n breast cancer and bone metastasis formation: implication of VEGF and osteoprotegerin. *Cancer Research*, **2011**, 71, 5728-38 | 10.1 | 59 |
| 82 | The HIF-1-inducible lysyl oxidase activates HIF-1 via the Akt pathway in a positive regulation loop and synergizes with HIF-1 in promoting tumor cell growth. *Cancer Research*, **2011**, 71, 1647-57 | 10.1 | 101 |
| 81 | Clinical and basic research papers □October 2011. *IBMS BoneKEy*, **2011**, 8, 428-432 | | |
| 80 | Early Bone Metastasis-Associated Molecular and Cellular Events **2010**, 41-45 | | 2 |
| 79 | Metastasis and bone loss: advancing treatment and prevention. *Cancer Treatment Reviews*, **2010**, 36, 615-20 | 14.4 | 100 |
| 78 | How do bisphosphonates inhibit bone metastasis in vivo?. *Neoplasia*, **2010**, 12, 571-8 | 6.4 | 54 |
| 77 | Nitrogen-containing bisphosphonates and cancer immunotherapy. *Current Pharmaceutical Design*, **2010**, 16, 3007-2014 | 3.3 | 30 |
| 76 | Development of a new ELISA for serum periostin: evaluation of growth-related changes and bisphosphonate treatment in mice. *Calcified Tissue International*, **2010**, 87, 341-50 | 3.9 | 21 |
| 75 | The molecular basis of bisphosphonate activity: a preclinical perspective. *Seminars in Oncology*, **2010**, 37 Suppl 1, S3-11 | 5.5 | 35 |
| 74 | Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts. *PLoS ONE*, **2010**, 5, e9741 | 3.7 | 87 |

| | | | |
|---|---|---|---|
| 73 | Integrins in bone metastasis formation and potential therapeutic implications. *Current Cancer Drug Targets*, **2009**, 9, 801-6 | 2.8 | 32 |
| 72 | Insights into the antitumor effects of bisphosphonates from preclinical models and potential clinical implications. *IBMS BoneKEy*, **2009**, 6, 210-217 | | 4 |
| 71 | Physiopathologie des mEastases osseuses. *Oncologie*, **2009**, 11, 10-15 | 1 | |
| 70 | Platelet is a major contributor to circulating levels of Dickkopf-1: clinical implications in patients with multiple myeloma. *British Journal of Haematology*, **2009**, 145, 264-6 | 4.5 | 42 |
| 69 | Nanostructured polyelectrolyte multilayer drug delivery systems for bone metastasis prevention. *Biomaterials*, **2009**, 30, 6367-73 | 15.6 | 34 |
| 68 | Bioactive lipids lysophosphatidic acid and sphingosine 1-phosphate mediate breast cancer cell biological functions through distinct mechanisms. *Oncology Research*, **2009**, 18, 173-84 | 4.8 | 33 |
| 67 | Cathepsin K inhibitors as treatment of bone metastasis. *Current Opinion in Supportive and Palliative Care*, **2008**, 2, 218-22 | 2.6 | 61 |
| 66 | Cell membrane proteomic analysis identifies proteins differentially expressed in osteotropic human breast cancer cells. *Neoplasia*, **2008**, 10, 1014-20 | 6.4 | 28 |
| 65 | Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. *Clinical Cancer Research*, **2008**, 14, 4658-66 | 12.9 | 87 |
| 64 | P49. Zoledronic acid-induced IPP accumulation in cancer cells strongly correlates with T-cell mediated cancer cell death. *Cancer Treatment Reviews*, **2008**, 34, 37 | 14.4 | 46 |
| 63 | Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. *Cancer Research*, **2008**, 68, 8945-53 | 10.1 | 39 |
| 62 | A convenient clinically relevant model of human breast cancer bone metastasis. *Clinical and Experimental Metastasis*, **2008**, 25, 33-42 | 4.7 | 28 |
| 61 | PathogEie des mEastases osseuses. *Revue Du Rhumatisme (Edition Francaise)*, **2008**, 75, 327-331 | 0.1 | |
| 60 | Increased Dickkopf-1 expression in breast cancer bone metastases. *British Journal of Cancer*, **2007**, 97, 964-70 | 8.7 | 150 |
| 59 | Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. *Breast Cancer Research and Treatment*, **2007**, 101, 135-48 | 4.4 | 94 |
| 58 | Bone metastasis: pathogenesis and therapeutic implications. *Clinical and Experimental Metastasis*, **2007**, 24, 599-608 | 4.7 | 119 |
| 57 | Advances in optical imaging and novel model systems for cancer metastasis research. *Clinical and Experimental Metastasis*, **2007**, 24, 699-705 | 4.7 | 44 |
| 56 | A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. *Cancer Research*, **2007**, 67, 9894-902 | 10.1 | 159 |

| | | | |
|---|---|---|---|
| 55 | Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. *Cancer Research*, **2007**, 67, 8742-51 | 10.1 | 169 |
| 54 | Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases. *Cancer Research*, **2007**, 67, 5821-30 | 10.1 | 166 |
| 53 | Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. *Journal of the National Cancer Institute*, **2007**, 99, 322-30 | 9.7 | 204 |
| 52 | International Society of Geriatric Oncology (SIOG) clinical practice recommendations for the use of bisphosphonates in elderly patients. *European Journal of Cancer*, **2007**, 43, 852-8 | 7.5 | 74 |
| 51 | Frequent low-dose bisphosphonate therapy. *Bone*, **2007**, 41, 901-2 | 4.7 | 2 |
| 50 | Bisphosphonates in cancer therapy. *Cancer Letters*, **2007**, 257, 16-35 | 9.9 | 165 |
| 49 | The type 1 lysophosphatidic acid receptor is a target for therapy in bone metastases. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 9643-8 | 11.5 | 175 |
| 48 | Antitumour Effects of Bisphosphonates **2006**, 345-350 | | |
| 47 | Transmigration: a new property of mature multinucleated osteoclasts. *Journal of Bone and Mineral Research*, **2006**, 21, 1913-23 | 6.3 | 31 |
| 46 | Expression and localisation of alphav integrins in human odontoblasts. *Cell and Tissue Research*, **2006**, 323, 457-63 | 4.2 | 18 |
| 45 | Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. *Cancer Research*, **2005**, 65, 4971-4 | 10.1 | 201 |
| 44 | Anti-tumour activity of zoledronic acid. *Cancer Treatment Reviews*, **2005**, 31 Suppl 3, 1-8 | 14.4 | 77 |
| 43 | Human breast tumors override the antiangiogenic effect of stromal thrombospondin-1 in vivo. *International Journal of Cancer*, **2005**, 116, 686-91 | 7.5 | 51 |
| 42 | Androgens repress the expression of the angiogenesis inhibitor thrombospondin-1 in normal and neoplastic prostate. *Cancer Research*, **2005**, 65, 300-8 | 10.1 | 52 |
| 41 | Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. *Journal of Clinical Investigation*, **2004**, 114, 1714-1725 | 15.9 | 317 |
| 40 | Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. *Journal of Clinical Investigation*, **2004**, 114, 1714-25 | 15.9 | 168 |
| 39 | In vitro and in vivo antitumor effects of bisphosphonates. *Current Medicinal Chemistry*, **2003**, 10, 173-80 | 4.3 | 68 |
| 38 | Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. *Journal of Biological Chemistry*, **2003**, 278, 45826-32 | 5.4 | 71 |

| | | | |
|---|---|---|---|
| 37 | SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. *Cancer Research*, **2003**, 63, 3919-22 | 10.1 | 182 |
| 36 | Activit anti-tumorale des bisphosphonates : mythe ou r alit . *Revue Du Rhumatisme (Edition Francaise)*, **2002**, 69, 997-1001 | 0.1 | |
| 35 | Integrin alpha(v)beta3 expression confers on tumor cells a greater propensity to metastasize to bone. *FASEB Journal*, **2002**, 16, 1266-8 | 0.9 | 202 |
| 34 | Mechanisms of bisphosphonate effects on osteoclasts, tumor cell growth, and metastasis. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2002**, 25, S3-9 | 2.7 | 91 |
| 33 | The antitumor potential of bisphosphonates. *Seminars in Oncology*, **2002**, 29, 33-42 | 5.5 | 84 |
| 32 | Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. *Cancer Research*, **2002**, 62, 6538-44 | 10.1 | 377 |
| 31 | Early detection of bone metastases in a murine model using fluorescent human breast cancer cells: application to the use of the bisphosphonate zoledronic acid in the treatment of osteolytic lesions. *Journal of Bone and Mineral Research*, **2001**, 16, 2027-34 | 6.3 | 134 |
| 30 | In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. *Genes and Development*, **2001**, 15, 1373-82 | 12.6 | 76 |
| 29 | Platelet-osteosarcoma cell interaction is mediated through a specific fibrinogen-binding sequence located within the N-terminal domain of thrombospondin 1. *Journal of Bone and Mineral Research*, **2000**, 15, 361-8 | 6.3 | 14 |
| 28 | M anismes d'action des bisphosphonates sur les cellules tumorales et perspectives d'utilisation dans le traitement de l'ost olyse maligne. *Revue Du Rhumatisme (Edition Francaise)*, **2000**, 67, 28-36 | 0.1 | |
| 27 | Decorin inhibits cell migration through a process requiring its glycosaminoglycan side chain **1999**, 75, 538-546 | | 73 |
| 26 | Additive antitumor activities of taxoids in combination with the bisphosphonate ibandronate against invasion and adhesion of human breast carcinoma cells to bone. *International Journal of Cancer*, **1999**, 83, 263-9 | 7.5 | 70 |
| 25 | CD36 mediates binding of soluble thrombospondin-1 but not cell adhesion and haptotaxis on immobilized thrombospondin-1. *Cell Biochemistry and Function*, **1998**, 16, 211-21 | 4.2 | 16 |
| 24 | Recent insights into the role of integrins in cancer metastasis. *Cellular and Molecular Life Sciences*, **1998**, 54, 541-8 | 10.3 | 83 |
| 23 | Identification of cell adhesive active sites in the N-terminal domain of thrombospondin-1. *Biochemical Journal*, **1997**, 321 ( Pt 3), 819-27 | 3.8 | 28 |
| 22 | Decorin inhibits cell attachment to thrombospondin-1 by binding to a KKTR-dependent cell adhesive site present within the N-terminal domain of thrombospondin-1. *Journal of Cellular Biochemistry*, **1997**, 67, 75-83 | 4.7 | 59 |
| 21 | Localization of thrombospondin, CD36 and CD51 during prenatal development of the human mammary gland. *Differentiation*, **1994**, 57, 133-41 | 3.5 | 8 |
| 20 | Thrombospondin (TSP1) mediates in vitro proliferation of human MG-63 osteoblastic cells induced by alpha-thrombin. *FEBS Letters*, **1993**, 329, 341-6 | 3.8 | 16 |

| | | | |
|---|---|---|---|
| 19 | The growth-supportive effect of thrombospondin (TSP1) and the expression of TSP1 by human MG-63 osteoblastic cells are both inhibited by dexamethasone. *FEBS Letters*, **1993**, 335, 161-6 | 3.8 | 9 |
| 18 | Osteonectin is an alpha-granule component involved with thrombospondin in platelet aggregation. *Journal of Bone and Mineral Research*, **1991**, 6, 1059-70 | 6.3 | 23 |
| 17 | Thrombospondin is synthesized and secreted by human osteoblasts and osteosarcoma cells. A model to study the different effects of thrombospondin in cell adhesion. *FEBS Journal*, **1989**, 181, 721-6 | | 45 |
| 16 | Complex formation of human thrombospondin with osteonectin. *FEBS Journal*, **1988**, 175, 275-84 | | 74 |
| 15 | Cell attachment and fibrinogen binding properties of platelet and endothelial cell thrombospondin are not affected by structural differences in the 70 and 18 kDa protease-resistant domains. *FEBS Letters*, **1988**, 228, 215-8 | 3.8 | 7 |
| 14 | Thrombospondin in milk, other breast secretions, and breast tissue. *Seminars in Thrombosis and Hemostasis*, **1987**, 13, 378-84 | 5.3 | 19 |
| 13 | Production, characterization, and use of monoclonal antibodies directed against human blood platelet thrombospondin: immunologic comparison with human endothelial and fibroblast thrombospondins. *Seminars in Thrombosis and Hemostasis*, **1987**, 13, 261-75 | 5.3 | 4 |
| 12 | Tandem purification of IgM monoclonal antibodies from mouse ascites fluids by anion-exchange and gel fast protein liquid chromatography. *Journal of Chromatography A*, **1986**, 354, 425-33 | 4.5 | 18 |
| 11 | Tandem purification of mouse IgM monoclonal antibodies produced in vitro using anion-exchange and gel fast protein liquid chromatography. *Journal of Chromatography A*, **1986**, 358, 209-18 | 4.5 | 11 |
| 10 | Characterization of two murine monoclonal antibodies (P10, P12) directed against different determinants on human blood platelet thrombospondin. *FEBS Journal*, **1986**, 154, 95-102 | | 28 |
| 9 | Structural and immunological comparison of human thrombospondins isolated from platelets and from culture supernatants of endothelial cells and fibroblasts. Evidence for a thrombospondin polymorphism. *FEBS Journal*, **1986**, 159, 569-79 | | 19 |
| 8 | Structural and immunological differences between human platelet and endothelial thrombospondins. *FEBS Letters*, **1986**, 196, 49-53 | 3.8 | 3 |
| 7 | Tandem separation of labelled human blood platelet membrane glycoproteins by anion-exchange and gel fast protein liquid chromatography. *Journal of Chromatography A*, **1985**, 326, 179-90 | 4.5 | 10 |
| 6 | One-step procedure for the rapid isolation of mouse monoclonal antibodies and their antigen binding fragments by fast protein liquid chromatography on a mono Q anion-exchange column. *Journal of Chromatography A*, **1985**, 319, 67-77 | 4.5 | 68 |
| 5 | Platelet membrane glycoprotein abnormalities in patients with myeloproliferative disorders and secondary thrombocytosis. *British Journal of Haematology*, **1985**, 60, 331-44 | 4.5 | 52 |
| 4 | Identification and characterization of fragments of major glycoproteins from platelet membrane after chymotrypsin treatment. *FEBS Journal*, **1985**, 148, 97-106 | | 15 |
| 3 | Isolation of thrombospondin released from thrombin-stimulated human platelets by fast protein liquid chromatography on an anion-exchange Mono-Q column. *Journal of Chromatography A*, **1984**, 296, 249-56 | 4.5 | 39 |
| 2 | A radioimmunoassay for thrombospondin, used in a comparative study of thrombospondin, beta-thromboglobulin and platelet factor 4 in healthy volunteers. *Thrombosis Research*, **1983**, 29, 569-81 | 8.2 | 83 |

| | | | |
|---|---|---|---|
| 1 | Tryptic peptide map analysis of the major human blood platelet membrane glycoproteins separated by two-dimensional polyacrylamide gel electrophoresis. *Biochimica Et Biophysica Acta - Biomembranes*, **1982**, 689, 513-22 | 3.8 | 12 |